top of page

GPCR News 

Post: Blog2_Post

Addex Therapeutics CEO Tim Dyer: There is a $4-bil market opportunity in dyskinesia

Updated: Aug 23, 2022

January 2022 "Watch our CEO Tim Dyer on AlphaStreet. In his interview, Mr. Dyer provides an overview of our #allostericmodulator pipeline and the potential $4 billion market for our lead compound #dipraglurant in #PDLID (#Parkinsonsdisease levodopa-induced #dyskinesia)."

Read more at the source

#DrGPCR #GPCR #IndustryNews

7 views0 comments

Recent Posts

See All

August 2022 "THOUSAND OAKS, Calif. and SAN CARLOS, Calif., Aug. 4, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., (NASDAQ: CCXI), a biopharmaceutical company focused on orally admin